Adrafinil

DB08925ApprovedWithdrawnSmall moleculeSympathomimetic-like Agent

Adrafinil is a mild central nervous system stimulating drug typically employed to relieve excessive sleepiness and inattention in geriatric patients. It is also been used off-label to prevent fatigue or... Adrafinil does not currently have FDA approval and is thus unregulated in the United States.

Mechanism: Pharmacologically active on Alpha-1 adrenergic receptors and Alpha adrenergic receptor
Curator reviewed
Primary indication: Used to relieve excessive sleepiness and inattention in elderly patients.Curator reviewed
Formula / weight: C₁₅H₁₅NO₃S · 289.35 g/mol (avg)
Code names: CRL-40028

Resolves to

Compound

UNIIBI81Z4542GCAS63547-13-7ChEMBLCHEMBL93077ChEBI135200KEGGD07348

Clinical / RWD

RxNorm45938ATCN06BX17

Structure

InChIKeyCGNMLOKEMNBUAI-UHFFFAOYSA-NSMILESONC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1

What you can answer from here — as of July 03, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

676Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 13 drug categories

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Adrafinil, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account